| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2025 | Dec, 2025 |
| Sales | 22,940 | 2,920 | 390 | 0 | 0 |
| Sales Growth | +685.62% | +648.72% | unch | unch | unch |
| Net Income | -37,160 | -91,670 | -77,960 | 0 | 0 |
| Net Income Growth | +59.46% | -17.59% | unch | unch | unch |
Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.